Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Mpg Vreeswijk"'
Publikováno v:
Journal of Pathology, 257(4), 403-412. WILEY
The role of pathology in patient management has evolved over time from the retrospective review of cells, tissue, and disease ('what happened') to a prospective outlook ('what will happen'). Examination of a static, two-dimensional hematoxylin and eo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0ec6e3d97ca270034926f534c9fc58
https://hdl.handle.net/1887/3505656
https://hdl.handle.net/1887/3505656
Autor:
A Llop-Guevara, Tjalling Bosse, N. ter Haar, Violeta Serra, N Campanini, Alexandra Leary, Benedetta Pellegrino, Antonino Musolino, E Yaniz-Galende, Claire J H Kramer, Mpg Vreeswijk
Publikováno v:
Translational research biomarkers.
Introduction/Background* RAD51 protein has been proposed as a functional readout of homologous recombination (HR) status using formalin-fixed paraffin embedded (FFPE) tumour tissue blocks. Recently, few laboratories have assessed the performance of R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f08d904bf11833ee87f4769f9894bc4
https://doi.org/10.1136/ijgc-2021-esgo.592
https://doi.org/10.1136/ijgc-2021-esgo.592
Autor:
Suzan Vrijaldenhoven, Joan B. Heijns, Mpg Vreeswijk, H de Graaf, S de Groot, Marij J. P. Welters, J.W.R. Nortier, Valter D. Longo, E van Leeuwen-Stok, R. T. Lugtenberg, J.E.A. Portielje, Hanno Pijl, LW Kessels, Arnold Baars, E. Meershoek-Klein Kranenbarg, J.J.M. van der Hoeven, Vthbm Smit, Ilina Ehsan, Hein Putter, A.L.T. Imholz, AJ van de Wouw, Judith R. Kroep, M. Duijm-de Carpentier
Publikováno v:
Cancer Research. 79:P1-15
Background: Short term fasting (STF) protects from toxicity, while enhancing the efficacy of chemotherapy in cancer bearing mice and is a promising strategy to enhance the efficacy and tolerability of chemotherapy in humans. A specifically designed l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ce71494cdb2109f6428f4f32eef67f5
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-20
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-20
Autor:
Mpg Vreeswijk, Tjalling Bosse, MM de Jonge, C.D. de Kroon, Violeta Serra, A Llop-Guevara, LM van Wijk, Cjh Kramer
Publikováno v:
ePoster Talks: Ovarian + Endometria.
Introduction/Background Homologous recombination deficiency (HRD) is frequent in non-endometrioid endometrial cancer (EC), justifying clinical trials testing PARP-inhibitors. To facilitate this development a pragmatic test to asses HR competency is r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d25dd5303ab57d50565eaef6472b4a8
https://doi.org/10.1136/ijgc-2019-esgo.64
https://doi.org/10.1136/ijgc-2019-esgo.64
Autor:
Trudy G. N. Jonges, LM van Wijk, Mpg Vreeswijk, Hans Clevers, Kadi Lõhmussaar, MJ van Roosmalen, M van de Ven, Johannes L. Bos, A van Oudenaarden, Oded Kopper, Nizar Hami, SA Revilla, Vwh Ho, Harry Begthel, Hjg Snippert, Wigard P. Kloosterman, J Espejo Valle-Inclan, Petronella O. Witteveen, P. J. Van Diest, Katja N. Gaarenstroom, Benjamin G. Neel, Harry Vrieling, Ronald P. Zweemer, Lennart Kester, Jeroen Korving, Tjalling Bosse, Natalie Proost, R Theeuwsen, Bas Ponsioen, CJ de Witte, Anjali Vanita Balgobind
Publikováno v:
Poster exhibition Day 2.
Introduction/Background Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumour heterogeneity of OC are limited and hard to establish. Methodology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57deabb996bdd1e521499647df9b82c0
https://doi.org/10.1136/ijgc-2019-esgo.182
https://doi.org/10.1136/ijgc-2019-esgo.182
Autor:
D Houtsma, A Jochems, Hanno Pijl, Jjwa Boei, Kjm van der Hoeven, G Gravesteijn, Judith R. Kroep, Mpg Vreeswijk, Hwr Nortier, S de Groot
Publikováno v:
Cancer Research. 73:P4-16
Background: Preclinical evidence shows that short-term fasting (STS) protects normal cells and makes cancer cells more vulnerable to chemotherapy. This pilot study examines the feasibility and the effects of STS on tolerance to chemotherapy in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e949585c89c6ba75a42b156b1c4a2cb6
https://doi.org/10.1158/0008-5472.sabcs13-p4-16-12
https://doi.org/10.1158/0008-5472.sabcs13-p4-16-12
Autor:
Maartje Los, Hein Putter, E van Leeuwen, Carolien H. Smorenburg, Joan B. Heijns, LW Kessels, N.I. Weijl, S de Groot, Judith R. Kroep, Ad A. Kaptein, E.M. Meershoek, Hanno Pijl, G.J. Liefers, Maarten J. Fischer, Hwr Nortier, Vthbm Smit, Mpg Vreeswijk, Cjh van de Velde, Agnes Jager, Valter D. Longo, A.L.T. Imholz, Kjm van der Hoeven, Jea Portielje
Publikováno v:
Cancer Research. 73:OT3-1
Background: Preclinical evidence shows that short-term fasting protects normal cells, while cancer cells are sensitized to chemotherapy. Furthermore, a specifically designed very low calorie, low amino acid substitution diet (“Fasting Mimicking Die
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ae86b129d5e558657578248d6eadcf6
https://doi.org/10.1158/0008-5472.sabcs13-ot3-1-03
https://doi.org/10.1158/0008-5472.sabcs13-ot3-1-03
Autor:
Parsons MT; Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. Electronic address: michael.parsons@qimrberghofer.edu.au., de la Hoya M; Molecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC, 28040 Madrid Spain., Richardson ME; Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA., Tudini E; Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Anderson M; Invitae Corporation, San Francisco, CA, USA., Berkofsky-Fessler W; GeneDx, Gaithersburg, MD, USA., Caputo SM; Department of Genetics, Institut Curie, and Paris Sciences Lettres Research University, 75005 Paris, France., Chan RC; Color Health, Burlingame, CA, USA., Cline MS; UC Santa Cruz Genomics Institute, Genomics, University of California, 1156 High Street, Santa Cruz, CA 95064, USA., Feng BJ; Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA., Fortuno C; Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Gomez-Garcia E; Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands., Hadler J; Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Hiraki S; GeneDx, Gaithersburg, MD, USA., Holdren M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Houdayer C; University Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics, FHU G4 Génomique, F-76000 Rouen, France., Hruska K; GeneDx, Gaithersburg, MD, USA., James P; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Karam R; Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA., Leong HS; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia., Martins A; University Rouen Normandie, Inserm U1245, F-76000 Rouen, France., Mensenkamp AR; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands., Monteiro AN; Department of Cancer Epidemiology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Nathan V; Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., O'Connor R; Color Health, Burlingame, CA, USA., Pedersen IS; Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Pesaran T; Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA., Radice P; Predictive Medicine: Molecular Bases of Genetic Risk, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133 Milano, Italy., Schmidt G; Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany., Southey M; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia; Department of Clinical Pathology, The Melbourne Medical School, The University of Melbourne, Melbourne, VIC 3010, Australia., Tavtigian S; Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA., Thompson BA; Department of Pathology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia., Toland AE; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH 43210, USA., Turnbull C; Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK., Vogel MJ; Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Weyandt J; Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA., Wiggins GAR; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand., Zec L; Natera, Inc, San Carlos, CA, USA., Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Walker LC; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand., Vreeswijk MPG; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands., Goldgar DE; Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA., Spurdle AB; Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. Electronic address: amanda.spurdle@qimrberghofer.edu.au.
Publikováno v:
American journal of human genetics [Am J Hum Genet] 2024 Sep 05; Vol. 111 (9), pp. 2044-2058. Date of Electronic Publication: 2024 Aug 13.
Autor:
Sanoguera-Miralles L; Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid (CSIC-UVa), Valladolid, Spain., Valenzuela-Palomo A; Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid (CSIC-UVa), Valladolid, Spain., Bueno-Martínez E; Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid (CSIC-UVa), Valladolid, Spain., Esteban-Sánchez A; Molecular Oncology Laboratory CIBERONC, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain., Lorca V; Molecular Oncology Laboratory CIBERONC, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain., Llinares-Burguet I; Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid (CSIC-UVa), Valladolid, Spain., García-Álvarez A; Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid (CSIC-UVa), Valladolid, Spain., Pérez-Segura P; Molecular Oncology Laboratory CIBERONC, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain., Infante M; Cancer Genetics, Instituto de Biología y Genética Molecular (CSIC-UVa), Valladolid, Spain., Easton DF; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, CB1 8RN, Cambridge, United Kingdom., Devilee P; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands., Vreeswijk MPG; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands., de la Hoya M; Molecular Oncology Laboratory CIBERONC, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain., Velasco-Sampedro EA; Splicing and Genetic Susceptibility to Cancer, Unidad de Excelencia Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas-Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.
Publikováno v:
Clinical chemistry [Clin Chem] 2024 Jan 04; Vol. 70 (1), pp. 319-338.
Autor:
van Wijk LM; Department of Human Genetics, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Vermeulen S; Department of Human Genetics, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Ter Haar NT; Department of Pathology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Kramer CJH; Department of Pathology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Terlouw D; Department of Pathology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Vrieling H; Department of Human Genetics, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Cohen D; Department of Pathology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands., Vreeswijk MPG; Department of Human Genetics, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands. M.P.G.Vreeswijk@lumc.nl.
Publikováno v:
Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Dec; Vol. 202 (3), pp. 607-616. Date of Electronic Publication: 2023 Sep 19.